Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Dimerix Limited ( (AU:DXB) ) has provided an announcement.
Dimerix Limited announced that CEO Dr. Nina Webster will present at the Euroz Hartley Healthcare Forum in Perth, highlighting their progress in developing treatments for kidney disease. The company’s focus on FSGS, a rare and severe kidney condition, is underscored by their proprietary DMX-200, which has shown promising results in clinical trials and received Orphan Drug Designation, positioning Dimerix for potential market exclusivity and development incentives in the US and Europe.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly kidney diseases. It is advancing its proprietary Phase 3 product candidate DMX-200 for FSGS kidney disease and DMX-700 for respiratory disease, utilizing its Receptor-HIT technology platform to identify new drug opportunities.
YTD Price Performance: 32.35%
Average Trading Volume: 2,334,349
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: A$251.3M
Find detailed analytics on DXB stock on TipRanks’ Stock Analysis page.